Parecoxib

Research use only, not for human use.

A potent and selective COX-2 inhibitor; a water-soluble prodrug of valdecoxib.

A potent and selective COX-2 inhibitor; a water-soluble prodrug of valdecoxib.Pain Approved(In Vitro):Parecoxib (0-200?μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells.Parecoxib (200?μM; 24-48 hours) results in a decreasee migratory ability of U343 cells than PBS-treated group.(In Vivo):Parecoxib (intraperitoneal injection; 2.5, 5.0 or 10 mg/kg; once a day; 21 days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10 mg/kg shows higher levels of percentage of time spent in the open arms.

Cell Viability Assay Cell Line:GBM cells: U251 and U343 cells Concentration:0 μM, 20 μM, 50 μM, 100 μM and 200?μM Incubation Time:24-48 hours Result:Resulted in a slower BrdU incorporation rate of GBM cells including U251 and U343 cells.

Parecoxib (intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10?mg/kg shows higher levels of percentage of time spent in the open arms. Animal Model:Naive adult male ICR mice, 15?weeks old and weighing 25-35?g Dosage:2.5, 5.0 or 10?mg/kg Administration:Intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days Result:Exerted an anxiolytic-like effect in the elevated plus-maze test.

SC-69124

Chromatin/Epigenetic

COX

COX-2

Neurological Disease

Pain

198470-84-7

370.4222

C19H18N2O4S

>98% (HPLC)

10 mM in DMSO

CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1

Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-

(-20℃)

With Ice Pack

≥ 2 years